Cisplatin is highly effective against disseminated gastric cancer and its study in combination therapy regimens is of interest in terms of increasing the effectiveness of chemotherapy for this insensitive group of tumors. It is relevant to study the activity of Cisplatin in combination with fluorinated drugs. Our work analyzed the experience of using the currently standard treatment regimen in European countries, including Cisplatin and daily infusions of 5-Fluorouracil. Data on the effectiveness and toxicity of a new regimen are presented, where infusions of 5-Fluorouracil are replaced by oral Xeloda.